(Cefepime + Taniborbactam hydrochloride) is a small molecule commercialized by Everest Medicines, with a leading Phase III program in Urinary Tract Infections. According to Globaldata, it is involved in 8 clinical trials, of which 7 were completed, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of (Cefepime + Taniborbactam hydrochloride)’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for (Cefepime + Taniborbactam hydrochloride) is expected to reach an annual total of $108 mn by 2032 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
(Cefepime + Taniborbactam hydrochloride) Overview
Fixed dose combination of cefepime and taniborbactam hydrochloride (VNRX-5133) is under development for the treatment of multi-drug resistant (MDR) gram-negative infections such as carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa infections, complicated urinary tract infections (cUTI) including acute pyelonephritis, pyuria, hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. It is administered intravenously. The therapeutic candidate acts by targeting beta lactamase and penicillin binding protein 2.
It was also under development for the treatment of complicated intra-abdominal infections (cIAI).
Everest Medicines Overview
Everest Medicines, is a biopharmaceutical company that licenses, develops and commercializes medicines for the treatment of cancer, autoimmune, cardio renal and infectious diseases. It is investigating Sacituzumab govitecan, an antibody-drug conjugate targeting metastatic triple-negative breast cancer (mTNBC), metastatic urothelial cancer (mUc), non-small cell lung cancer (NSCLC) and other oncology indications; and FGF401 for hepatocellular carcinoma. The company is evaluating Etrasimod to treat ulcerative colitis and other autoimmune diseases; Nefecon for IgA nephropathy; Ralinepag against pulmonary arterial hypertension (PAH). Everest Medicines is also developing drugs for community-acquired bacterial pneumonia (CABP), complicated urinary tract infection (cUTi) and other infectious diseases. It works in partnership with Immunomedics, Novartis, Arena Pharmaceuticals and other companies to develop its products. Everest Medicines is headquartered in Shanghai, China.
The company reported revenues of (Renminbi) CNY0.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was CNY1,026.3 million in FY2021, compared to an operating loss of CNY688.5 million in FY2020. The net loss of the company was CNY1,008.7 million in FY2021, compared to a net loss of CNY5,658.2 million in FY2020.
For a complete picture of (Cefepime + Taniborbactam hydrochloride)’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.